UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

The Lancet (British edition), 2012-08, Vol.380 (9842), p.651-659

2012

Link zum Volltext

Verfügbarkeit prüfen

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

The New England journal of medicine, 2017-10, Vol.377 (17), p.1613-1629

2017

Link zum Volltext

Verfügbarkeit prüfen

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2016-10, Vol.388 (10056), p.2128-2141

2016

Link zum Volltext

Verfügbarkeit prüfen

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

The lancet respiratory medicine, 2015-05, Vol.3 (5), p.355-366

2015

Link zum Volltext

Verfügbarkeit prüfen

Specific IgE against Staphylococcus aureus enterotoxins: An independent risk factor for asthma

Journal of allergy and clinical immunology, 2012-08, Vol.130 (2), p.376-381.e8

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

The lancet respiratory medicine, 2015-09, Vol.3 (9), p.692-701

2015

Link zum Volltext

Verfügbarkeit prüfen

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

The New England journal of medicine, 2015-05, Vol.372 (21), p.1987-1995

2015

Link zum Volltext

Verfügbarkeit prüfen

Against all odds: anti-IgE for intrinsic asthma?

Thorax, 2014-01, Vol.69 (1), p.94-96

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Drug safety, 2020-05, Vol.43 (5), p.409-425

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

Clinical therapeutics, 2019-10, Vol.41 (10), p.2041-2056.e5

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

Respiratory medicine, 2014-04, Vol.108 (4), p.584-592

2014

Link zum Volltext

Verfügbarkeit prüfen

The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline

Respiratory medicine, 2016-05, Vol.114, p.27-37

2016

Link zum Volltext

Verfügbarkeit prüfen

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

Respiratory medicine, 2011-05, Vol.105 (5), p.719-726

2011

Link zum Volltext

Verfügbarkeit prüfen

Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma

Respiratory research, 2022-03, Vol.23 (1), p.45-45, Article 45

2022

Link zum Volltext

Verfügbarkeit prüfen

Apprendre l’hygiène

In situ (Paris), 2023-09, Vol.51

Korn, Stéphanie

2023

Link zum Volltext

Verfügbarkeit prüfen

Reslizumab as add-on therapy in patients with refractory asthma

BMJ open respiratory research, 2020-04, Vol.7 (1), p.e000494

2020

Link zum Volltext

Verfügbarkeit prüfen

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists

The World Allergy Organization journal, 2023-12, Vol.16 (12), p.100844-100844, Article 100844

2023

Link zum Volltext

Verfügbarkeit prüfen

Measurement of exhaled nitric oxide: Comparison of different analysers

Respirology (Carlton, Vic.), 2010-11, Vol.15 (8), p.1203-1208

2010

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

Annals of allergy, asthma, & immunology, 2011-12, Vol.107 (6), p.474-479.e2

2011

Link zum Volltext

Verfügbarkeit prüfen

CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.521-528.e7

2012

Link zum Volltext

Verfügbarkeit prüfen

Reply to the Letter Entitled “FeNO Variability when Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff”

Respiration, 2020-01, Vol.99 (1), p.94-94

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study

Chest, 2014-03, Vol.145 (3), p.375A-1-375A-2

2014

Link zum Volltext

Verfügbarkeit prüfen

Benralizumab, an anti-interleukin-5 receptor [alpha] monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2016-10, Vol.388 (10056), p.2128

2016

Link zum Volltext

Verfügbarkeit prüfen

German Asthma Net – Was haben wir bisher gelernt?

Pneumologe, 2023-03, Vol.20 (2), p.88-93

2023

Link zum Volltext

Verfügbarkeit prüfen

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

The New England journal of medicine, 2017-06, Vol.376 (25), p.2448-2458

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(85)
Humans
(72)
Asthma
(43)
Female
(42)
Male
(41)
Respiratory System
(40)
Adult
(36)
Middle Aged
(36)
Asthma - Drug Therapy
(29)
Aged
(26)
Double-Blind Method
(21)
Patients
(20)
Immunology
(19)
Anti-Asthmatic Agents - Therapeutic Use
(18)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Treatment Outcome
(17)
Allergy
(16)
Child
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

Specific IgE against Staphylococcus aureus enterotoxins: An independent risk factor for asthma

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

Against all odds: anti-IgE for intrinsic asthma?

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma

Apprendre l’hygiène

Reslizumab as add-on therapy in patients with refractory asthma

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists

Measurement of exhaled nitric oxide: Comparison of different analysers

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease

Reply to the Letter Entitled “FeNO Variability when Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff”

Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study

Benralizumab, an anti-interleukin-5 receptor [alpha] monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

German Asthma Net – Was haben wir bisher gelernt?

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

Suchergebnisse filtern